RecruitingNCT05332756

Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)

Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives

Sponsor

Beijing Tiantan Hospital

Enrollment

400 participants

Start Date

May 1, 2022

Study Type

OBSERVATIONAL

Conditions

Moyamoya Disease

Summary

The purpose of this study is to investigate the long-term outcomes of conservative management in patients with moyamoya disease and their first-degree relatives, and provide potential pathogenesis of moyamoya disease.

Eligibility

Min Age: 2 YearsMax Age: 60 Years

Inclusion Criteria5

Patients with age between 2-60 years;
A clinical diagnosis of moyamoya disease, including unilateral and bilateral disease.
Patients are medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
Capable of understanding the purpose and risk of the study and has signed the informed consent. If the participant is not capable of this at the time of enrollment, a legally authorized representative will provide written informed consent in accordance with all regulations.
Ability to comply with study follow-up.

Exclusion Criteria7

Concomitant other diseases, including systemic vasculitis, neurofibroma, meningitis, sickle cell disease, down's syndrome, and previous basilar radiotherapy.
Patients with cardiogenic embolism, including a history of atrial fibrillation, valvular disease or cardiac valve replacement.
Patients are allergic to the contrast agents.
Patients are treated with direct, indirect, or combined revascularization depending on the presentation.
Physical or subjective failure to cooperate with the examination or serious comorbid diseases.
Patients are unable or unlikely to return for follow-up visits.
Any other reasons that, in the opinion of the investigators, make the participant unsuitable for enrollment.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERConservative management

Patients and their first-degree relatives will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.